Medpace Investors Face June 8 Deadline To Seek Lead Role in Securities Suit

Overview

• Robbins Geller, Rosen Law, and Glancy Prongay, which issued fresh notices Thursday and Friday, urge Medpace shareholders to move by June 8 to seek lead-plaintiff status in Durbin v. Medpace in the Southern District of Ohio.
• The complaint claims Medpace misled investors about rising backlog cancellations and promoted a fourth‑quarter 2025 book‑to‑bill target of 1.15 as reasonable despite contrary trends.
• Medpace reported a 1.04 book‑to‑bill on February 9, 2026 and cited the highest cancellation levels in over a year, and the stock fell 15.9% the next day to close at $446.05.
• Book‑to‑bill compares new project bookings to billed work, so cancellations reduce new awards that stick and can quickly pull the ratio down, reshaping growth expectations for a contract research firm.
• The putative class spans April 22, 2025 through February 9, 2026, and no class has been certified, so investors may choose any counsel or remain absent class members for now.